Isofol’s Board of Directors resolve on a fully guaranteed preferential rights issue of approximately SEK 150 million
GOTHENBURG, Sweden, May 7, 2020 - Isofol Medical AB’s (publ) (Nasdaq First North Premier Growth Market: ISOFOL) (“Isofol” or the “Company”) Board of Directors have today, pursuant to the authorization granted by the extra general meeting on May 5, 2020, resolved on a fully guaranteed new share issue of a maximum of 42,739,736 shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The subscription price in the Rights Issue is SEK 3.5 per share. Through the Rights Issue, the Company will receive approximately SEK 150 million before transaction costs